Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | GLP1R | P43220 | 8/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25697749 | 1.00 | MEN1 (0.46) | MEN1KMT2AGLP1RGAAUSP2 | |
| SCHEMBL24673214 | 0.90 | MEN1 (0.44) | MEN1KMT2AGLP1RGAA | |
| SCHEMBL25921460 | 0.90 | MEN1 (0.44) | MEN1KMT2AGLP1RTSHR | |
| SCHEMBL22861656 | 0.87 | KMT2A (0.50) | MEN1KMT2AGLP1R | |
| SCHEMBL21106646 | 0.87 | KMT2A (0.50) | MEN1KMT2AGLP1R | |
| SCHEMBL22861621 | 0.87 | MEN1 (0.42) | MEN1KMT2AGLP1RGAA | |
| SCHEMBL24765414 | 0.86 | MEN1 (0.51) | MEN1KMT2AGLP1RGAAUSP2 | |
| SCHEMBL25885537 | 0.85 | MEN1 (0.50) | MEN1KMT2AGLP1RGAAUSP2 | |
| SCHEMBL24764324 | 0.83 | KMT2A (0.49) | MEN1KMT2AGLP1RGAAUSP2 | |
| SCHEMBL17853874 | 0.82 | KMT2A (0.66) | MEN1KMT2AGAAUSP2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230149549-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-05-18 | — | — | US | disclosed |
| US-20210228562-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2021-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230149549-A1 | SMARCA DEGRADERS AND USES THEREOF | SMARCA1, SMARCB1, SMARCE1 | MEN1 1517/4885KMT2A 310/4885GLP1R 4289/4885 |
| US-20210228562-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | MEN1 4055/4885KMT2A 445/4885GLP1R 2955/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.